Get the Stockscreener App
6.47
0.31%
-0.02
Immucell Corp stock is traded at $6.47, with a volume of 1,356.
It is down -0.31% in the last 24 hours and up +22.77% over the past month.
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
See More
Previous Close:
$6.49
Open:
$6.5
24h Volume:
1,356
Relative Volume:
0.06
Market Cap:
$58.02M
Revenue:
$23.84M
Net Income/Loss:
$-3.81M
P/E Ratio:
-12.94
EPS:
-0.5
Net Cash Flow:
$-713.00K
1W Performance:
+0.78%
1M Performance:
+22.77%
6M Performance:
+37.95%
1Y Performance:
+54.78%
1-Day Range:
$6.50
$6.5771
1-Week Range:
$6.1429
$6.5771
52-Week Range:
$3.34
$7.0063
Immucell Corp Stock (ICCC) Company Profile
Name
Immucell Corp
Sector
Industry
Phone
(207) 878-2770
Address
56 EVERGREEN DR, PORTLAND, ME
Compare ICCC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICCC
Immucell Corp
|
6.55 | 58.02M | 23.84M | -3.81M | -713.00K | -0.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.06 | 114.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
533.82 | 55.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
305.14 | 39.64B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.44 | 35.64B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
267.52 | 28.55B | 3.81B | -644.79M | -669.77M | -6.24 |
Immucell Corp Stock (ICCC) Latest News
Immucell director Bryan Gathagan acquires $6,320 in shares By Investing.com - Investing.com India
Immucell director Bryan Gathagan acquires $6,320 in shares - Investing.com
ImmuCell expands First Defense team - Feedstuffs
Citadel Advisors LLC Invests $149,000 in ImmuCell Co. (NASDAQ:ICCC) - Defense World
ImmuCell stock soars to 52-week high, touches $7 mark - Investing.com
Northern Trust Corp Increases Stake in ImmuCell Co. (NASDAQ:ICCC) - Defense World
ImmuCell (NASDAQ:ICCC) Shares Pass Above 200 Day Moving Average – Here’s What Happened - Defense World
ImmuCell stock soars to 52-week high, touches $5.97 By Investing.com - Investing.com Canada
ImmuCell stock soars to 52-week high, touches $5.97 - Investing.com
ImmuCell Reports Y/Y Q1 Earnings Growth on Record Sales & Margin Gains - Yahoo Finance
ImmuCell Reports Y/Y Q1 Earnings Growth On Record Sales & Margin Gains - Barchart.com
Dimensional Fund Advisors LP Has $341,000 Stock Position in ImmuCell Co. (NASDAQ:ICCC) - Defense World
ImmuCell Corporation (NASDAQ:ICCC) Q1 2025 Earnings Call Transcript - Insider Monkey
Earnings call transcript: ImmuCell’s Q1 2025 revenue hits record, stock surges - Investing.com
ImmuCell Q2 2025 slides: sales momentum continues as Re-Tain awaits FDA approval - Investing.com Canada
ImmuCell Corp Q1 2025 Earnings: EPS at $0.16, Revenue Hits $8.1 Million - GuruFocus
ImmuCell Corporation Q1 2025 Financial Results - TradingView
ImmuCell To Announce Unaudited Financial Results For the Quarter Ended March 31, 2025 - Barchart.com
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025 - Stock Titan
Geode Capital Management LLC Boosts Stock Holdings in ImmuCell Co. (NASDAQ:ICCC) - Defense World
ImmuCell Co. (NASDAQ:ICCC) Short Interest Update - Defense World
ImmuCell (NASDAQ:ICCC) Stock Crosses Above 200-Day Moving Average – Should You Sell? - Defense World
The Zacks Analyst Blog Netflix, SAP SE, Shell, Preformed Line Products and ImmuCell - Yahoo Finance
ImmuCell (NASDAQ:ICCC) Stock Crosses Above 200 Day Moving Average – What’s Next? - Defense World
ImmuCell reports record sales in first quarter of 2025 - Investing.com
Record Quarter: ImmuCell Crushes Sales Estimates with $8.1M Revenue Milestone - Stock Titan
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025 - The Globe and Mail
ImmuCell appoints new CFO to bolster growth strategy - Investing.com
ImmuCell Strengthens Leadership: 24-Year IDEXX Finance Expert Takes CFO Role - Stock Titan
ImmuCell Hires Chief Financial Officer - The Globe and Mail
ImmuCell Full Year 2024 Earnings: US$0.26 loss per share (vs US$0.74 loss in FY 2023) - Yahoo Finance
Revolutionary Antibiotic-Free Mastitis Treatment Enters Market Testing Phase - Stock Titan
IMMUCELL CORP /DE/ SEC 10-K Report - TradingView
ImmuCell (NASDAQ:ICCC) Stock Passes Above 200 Day Moving Average – Time to Sell? - Defense World
ImmuCell (NASDAQ:ICCC) Stock Price Passes Above 200-Day Moving Average – Should You Sell? - Defense World
ImmuCell Corp. to Host Earnings Call - ACCESS Newswire
ImmuCell Posts Y/Y Q4 Earnings Growth, Awaits FDA Approval for Re-Tain - Yahoo Finance
ImmuCell Corp (ICCC) Q4 2024 Earnings Call Highlights: Strong Sales Growth and Operational ... By GuruFocus - Investing.com Canada
ImmuCell Corporation (NASDAQ:ICCC) Q4 2024 Earnings Call Transcript - Insider Monkey
Earnings call transcript: ImmuCell sees strong Q4 2024 sales growth - Investing.com
ImmuCell Corporation Reports Strong Financial Performance for Q4 and Full Year 2024 - TradingView
Animal Health Pioneer ImmuCell Sets Stage for Critical Year-End Financial Reveal - StockTitan
The Zacks Analyst Blog Highlights Apple, Eli Lilly, Shopify and ImmuCell - Yahoo Finance
Top Stock Reports for Apple, Eli Lilly & Shopify - Yahoo Finance
ImmuCell (NASDAQ:ICCC) Stock Price Passes Above 200-Day Moving Average – Here’s What Happened - Defense World
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
ImmuCell (NASDAQ:ICCC) Stock Passes Above 200 Day Moving Average – What’s Next? - Defense World
ImmuCell Settles Insurance Claim for Production Contamination Events - Defense World
ImmuCell settles insurance claim for production losses - Investing.com
ImmuCell Secures $426,587 Additional Insurance Settlement for Production Contamination Issues - StockTitan
Immucell Corp Stock (ICCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.97%
0.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):